Vera Therapeutics Inc
VERA20.160USD
-0.790-3.77%
交易中 （美東）報價延遲15分鐘
1.29B總市值
虧損本益比TTM
關於 Vera Therapeutics Inc 公司
Vera Therapeutics, Inc. 是一家後期生物技術公司。該公司專注於開發和商業化針對嚴重免疫疾病患者的變革性療法。其主要候選產品是阿塞西普，這是一種融合蛋白，每週皮下注射一次，可阻斷 B 細胞活化因子 (BAFF) 和 A 增殖誘導配體 (APRIL)，後者可刺激 B 細胞產生自身抗體，導致某些自身免疫性疾病，包括 IgAN（也稱爲伯傑氏病）和狼瘡性腎炎。此外，該公司正在評估其他疾病，在這些疾病中，阿塞西普減少自身抗體可能具有醫學用途。該公司還致力於開發 MAU868，這是一種單克隆抗體，旨在中和 BK 病毒 (BKV) 感染，BKV 是一種多瘤病毒，在某些情況下（例如腎移植）可能會造成毀滅性後果。該公司保留阿塞西普和 MAU868 的所有全球開發和商業權利。
公司簡介
公司代碼VERA
公司名稱Vera Therapeutics Inc
上市日期May 14, 2021
CEODr. Marshall Fordyce, M.D.
員工數量112
證券類型Ordinary Share
年結日May 14
公司地址2000 Sierra Point Parkway, Suite 1200
城市BRISBANE
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94005
電話16507700077
網址https://veratx.com/
公司代碼VERA
上市日期May 14, 2021
CEODr. Marshall Fordyce, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
287.51K
-9.77%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
-89.68%
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
Independent Director
Independent Director
17.49K
--
Ms. Christy Oliger
Ms. Christy Oliger
Independent Director
Independent Director
--
--
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. William D. Turner
Mr. William D. Turner
Chief Development Officer
Chief Development Officer
--
--
Mr. David Louis Johnson
Mr. David Louis Johnson
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Sean P. Grant
Mr. Sean P. Grant
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Kimball Hall
Ms. Kimball Hall
Independent Director
Independent Director
--
--
Dr. Robert M. (Rob) Brenner, M.D.
Dr. Robert M. (Rob) Brenner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
287.51K
-9.77%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
-89.68%
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
Independent Director
Independent Director
17.49K
--
Ms. Christy Oliger
Ms. Christy Oliger
Independent Director
Independent Director
--
--
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. William D. Turner
Mr. William D. Turner
Chief Development Officer
Chief Development Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月28日 週一
更新時間: 7月28日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Avoro Capital Advisors LLC
8.94%
Longitude Capital Management Co., LLC
8.07%
T. Rowe Price Associates, Inc.
7.36%
BlackRock Institutional Trust Company, N.A.
5.62%
Deerfield Management Company, L.P.
5.25%
Other
64.76%
持股股東
持股股東
佔比
Avoro Capital Advisors LLC
8.94%
Longitude Capital Management Co., LLC
8.07%
T. Rowe Price Associates, Inc.
7.36%
BlackRock Institutional Trust Company, N.A.
5.62%
Deerfield Management Company, L.P.
5.25%
Other
64.76%
股東類型
持股股東
佔比
Investment Advisor
34.41%
Hedge Fund
31.30%
Investment Advisor/Hedge Fund
30.28%
Venture Capital
12.85%
Corporation
3.00%
Research Firm
2.19%
Individual Investor
1.05%
Private Equity
0.75%
Pension Fund
0.23%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
380
74.98M
117.56%
-3.36M
2025Q1
382
72.82M
114.18%
-4.50M
2024Q4
363
73.64M
115.55%
+5.56M
2024Q3
344
64.32M
116.69%
-4.00M
2024Q2
326
63.69M
115.63%
-1.15M
2024Q1
280
61.43M
112.19%
+9.50M
2023Q4
210
49.91M
111.09%
+1.94M
2023Q3
190
48.72M
112.47%
-1.60M
2023Q2
180
47.50M
110.63%
+142.39K
2023Q1
161
46.72M
108.87%
+12.76M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Avoro Capital Advisors LLC
5.70M
8.94%
+91.90K
+1.64%
Mar 31, 2025
Longitude Capital Management Co., LLC
5.14M
8.07%
--
--
Oct 31, 2024
T. Rowe Price Associates, Inc.
4.70M
7.36%
+373.15K
+8.63%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.59M
5.62%
+33.98K
+0.96%
Mar 31, 2025
Deerfield Management Company, L.P.
3.35M
5.25%
+2.30M
+218.87%
Jun 06, 2025
Fidelity Management & Research Company LLC
3.23M
5.07%
+179.19K
+5.87%
Mar 31, 2025
The Vanguard Group, Inc.
2.91M
4.56%
-31.14K
-1.06%
Mar 31, 2025
Sofinnova Investments, Inc
2.79M
4.38%
--
--
Mar 31, 2025
Commodore Capital LP
2.56M
4.02%
+603.18K
+30.80%
Mar 31, 2025
Vestal Point Capital, LP
2.50M
3.92%
+1.43M
+132.56%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ALPS Medical Breakthroughs ETF
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
SPDR S&P Biotech ETF
0.43%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
ProShares Ultra Nasdaq Biotechnology
0.17%
Invesco Nasdaq Biotechnology ETF
0.17%
iShares Biotechnology ETF
0.12%
T Rowe Price Small-Mid Cap ETF
0.08%
iShares Russell 2000 Growth ETF
0.08%
Optimize Strategy Index ETF
0.07%
查看更多
ALPS Medical Breakthroughs ETF
佔比1.02%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.94%
SPDR S&P Biotech ETF
佔比0.43%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.25%
ProShares Ultra Nasdaq Biotechnology
佔比0.17%
Invesco Nasdaq Biotechnology ETF
佔比0.17%
iShares Biotechnology ETF
佔比0.12%
T Rowe Price Small-Mid Cap ETF
佔比0.08%
iShares Russell 2000 Growth ETF
佔比0.08%
Optimize Strategy Index ETF
佔比0.07%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
